In this respect, patients from the Göttingen EPO Stroke Study that did not receive thrombolysis but were treated with erythropoietin (EPO) showed significantly lower GFAP concentrations over 7 days, suggesting a beneficial effect of EPO in patients with IS [46]. This evidence concerns the gene GFAP and Stroke.